Indivior PLC is a pharmaceutical company. The Company is engaged in developing medicines to treat substance use disorders (SUD), serious mental illnesses, and opioid overdose. It has a pipeline of product candidates designed to address other chronic conditions and co-occurring disorders of SUD, including alcohol use disorder and cannabis use disorder, and co-morbidities, including schizophrenia. Its core products include SUBLOCADE (buprenorphine extended release) monthly injection; SUBOXONE Film (buprenorphine and naloxone sublingual film); SUBOXONE Tablet (buprenorphine and naloxone sublingual tablets), and SUBUTEX Tablet (buprenorphine sublingual tablets). Its products for the treatment of opioid disorders (OUD) are OPVEE (nalmefene) nasal spray for opioid overdose reversal, and PERSERIS (risperidone) extended-release injectable suspension for the treatment of schizophrenia in adults in the United States. Its portfolio of products is available in 37 countries.
종목 코드 INDV
회사 이름Indivior PLC
상장일Dec 24, 2014
CEOMr. Joseph J. (Joe) Ciaffoni
직원 수1030
유형Ordinary Share
회계 연도 종료Dec 24
주소234 Bath Road
도시SLOUGH
증권 거래소NASDAQ Global Select Consolidated
국가United Kingdom
우편 번호SL1 4EE
전화448043791090
웹사이트https://www.indivior.com/en
종목 코드 INDV
상장일Dec 24, 2014
CEOMr. Joseph J. (Joe) Ciaffoni
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.

데이터 없음